Clinical Trial Update: Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas [Phase 2]

View source ↗

Summary

Phase 2 trial update of talabostat in combination with gemcitabine for stage IV pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma
• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Talabostat (talabostat)

Snippet

Sponsor: Point Therapeutics | Conditions: Pancreatic Cancer, Neoplasm Metastasis | Phase 2 | Status: TERMINATED